County Bk Greenwood S C Com COYA 深 滬
等待開盤 10-16 09:30:00 美东时间
6.71
-0.490
-6.81%
華盛通- 最 高7.17
- 今 開7.17
- 成交量 20.93万股
- 最 低 6.5401
- 昨 收 7.20
- 總市值 1.12亿
- 52周最高 10.24
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 4.65
- 委 比 -50.67%
- 總股本 1672.51万
- 歷史最高 10.6899
- 量 比 0.67
- 振 幅 8.75%
- 歷史最低 3.21
- 每 手 1
- 風險率 0.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Coya Therapeutics jumps as Greenlight discusses in Q3 letter
Coya Therapeutics (NASDAQ:COYA) surged 17% after David Einhorn's Greenlight hedge fund disclosed it's the company's largest holder in its lastest Q3 letter to investors. Coya's lead drug is aimed at t...
10-14 23:09
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
Coya Therapeutics Completes Patient Enrollment Of Investigator-Initiated, Open-Label Study With Low-Dose IL-2 And CTLA4-Ig Combination Treatment In Patients With Mild To Moderate Frontotemporal Dementia
Following the positive interim results in 5 patients announced earlier this year, a total of 9 patients have been enrolled as plannedThe study is progressing according to protocol, and no safety issues have been
09-29 20:20
EXCLUSIVE: Coya Therapeutics Investigational Combination Therapy With GLP-1 Shows Potential For Alzheimer's Disease
Coya's COYA 303 showed strong immune modulation and reduced inflammation in the brain, supporting its development for neurodegenerative diseases like Alzheimer's.
09-16 19:45
Coya Therapeutics' Upcoming Phase 2 Clinical Trial To Evaluate Efficacy And Safety Of COYA 302 In Patients With ALS Accepted As NEALS-Affiliated Trial By NEALS Consortium
NEALS, the world's largest ALS research consortium, has selected the COYA 302 trial and it is now affiliated with NEALS as part of its mission to accelerate the development of new treatments for people living with
09-04 20:14
What's Going On With Coya Therapeutics Stock?
Shares of Coya Therapeutics are trading higher Monday morning. The company provided an update regarding the development of a new treatment for Amyotrophic Lateral Sclerosis.
08-25 21:57
HC Wainwright & Co. Reiterates Buy on Coya Therapeutics, Maintains $18 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $18 price target.
08-25 19:25
Chardan Capital Maintains Buy on Coya Therapeutics, Maintains $14 Price Target
Chardan Capital analyst Keay Nakae maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $14 price target.
08-13 22:28
Coya Therapeutics Q2 EPS $(0.36) Beats $(0.42) Estimate, Sales $163.616K Miss $940.000K Estimate
Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.42) by 13.46 percent. This is a 89.47 percent decrease over losses of $(0.19) per share from
08-12 20:05
沙特设立高端餐饮新规，拓展经济多元化路径
①沙特发布精致餐饮新规，明确设立专属营业许可和运营标准，推动高端餐饮纳入经济多元化发展路径； ②国际品牌与本土创业者共同布局，带动高端餐饮与供应链、商业地产等相关行业协同增长。
07-28 13:11
